Research programme: biphosphonate-vitamin B6 conjugates - MBC Pharma
Alternative Names: MBC-31; MBC-4Latest Information Update: 28 Mar 2025
At a glance
- Originator MBC Pharma
- Class Anti-infectives
- Mechanism of Action Bone resorption factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Bone disorders; Osteomyelitis
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Bone-disorders in USA (PO)
- 28 Mar 2025 No recent reports of development identified for preclinical development in Osteomyelitis in USA (PO)
- 22 Feb 2023 Preclinical development is ongoing in the US